(OMER) Omeros Corporation BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(OMER) Omeros Corporation Complete Analysis Pack
Visual. Strategic. Downloadable.
This Omeros Corporation BCG Matrix helps you quickly see how the company’s products or business units may be positioned across Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Narsoplimab, HSCT-TMA, pivotal trials completed
Narsoplimab is Omeros Corporation’s lead late-stage asset and the clearest Star in its pipeline. In HSCT-TMA, an ultra-rare post-transplant complication with no approved U.S. therapy, pivotal studies are complete, which lowers clinical risk. If approved, it could win strong share in a tiny but high-value niche; Omeros has already reported positive late-stage data and is pushing for regulatory review.
Narsoplimab, MASP-2 inhibitor, first-in-class
Narsoplimab is Omeros Corporation’s first-in-class MASP-2 inhibitor, so it blocks the lectin pathway at a precise rare-disease target. In 2025, that niche focus still matters because specialty hematology and transplant care rewards drugs with clear mechanistic differentiation. That first-in-class profile can speed uptake if clinical and regulatory traction holds. In BCG terms, it fits the best Star case in the portfolio.
HSCT-TMA, orphan indication, high unmet need
HSCT-TMA is a rare, medically severe complication of stem cell transplant, so it fits an orphan market with high unmet need. Omeros has pushed narsoplimab farther here than most of its other programs, with FDA orphan and breakthrough designations supporting the asset. In specialty orphan care, one clear leader can capture most use if the data hold up.
Complement-mediated rare diseases, core focus area
Omeros Corporation is built around complement biology, so this is its clearest Star. The niche covers several rare diseases with few approved options, which keeps pricing power and unmet need high. If late-stage data keeps holding, the platform can turn a small pipeline into a meaningful revenue base.
- Core focus: complement pathway
- Rare diseases, limited therapies
- High upside if trials succeed
Narsoplimab franchise, multiple follow-on indications
Narsoplimab is more than a one-shot HSCT-TMA asset: Omeros has taken the same lectin-pathway inhibitor into at least 3 follow-on areas, including IgA nephropathy and antibody-mediated rejection. That breadth raises the odds that one molecule becomes a durable franchise, which is the clearest Star pattern in the pipeline.
- Same drug, multiple shots at success
- 3+ follow-on indications widen value
- One approved win could anchor the franchise
Narsoplimab: Omeros’ Star Asset With Rare-Disease Upside
Narsoplimab is Omeros Corporation’s clear Star: it targets HSCT-TMA, a rare, severe transplant complication with no approved U.S. therapy. Its late-stage data and orphan-style niche support a high-share launch if regulators approve it. The same MASP-2 drug also has follow-on shots in IgA nephropathy and antibody-mediated rejection, which can extend value beyond one use case.
| Star driver | Latest proof |
|---|---|
| Lead asset | Narsoplimab |
| Core market | HSCT-TMA |
| Unmet need | No approved U.S. therapy |
| Expansion shots | IgA nephropathy, AMR |
What is included in the product
Detailed Word Document
Omeros Corporation BCG Matrix: concise view of Stars, Cash Cows, Question Marks, and Dogs with invest/hold/divest guidance.
Editable Excel File
Quick BCG snapshot of Omeros Corporation to spot portfolio pain points fast
Reference Sources
Gives a credible source trail for Omeros Corporation, helping users verify claims fast and make better decisions with confidence.
Cash Cows
OMIDRIA, approved U.S. ophthalmology product
OMIDRIA is Omeros Corporation’s only commercial product and its clearest cash generator. In a U.S. cataract market with about 4 million surgeries a year, a niche, physician-driven brand needs less selling spend, which fits the Cash Cow profile. Omeros also said OMIDRIA has been used in over 1 million procedures, showing durable demand and repeat use.
OMIDRIA, cataract-surgery niche
OMIDRIA fits Omeros Corporation's Cash Cow profile: it is used in a narrow cataract-surgery setting, not a broad mass market, so demand is tied to established physician and facility use. Once adopted, specialty products like this can stay steady, and OMIDRIA has shown mature, not explosive, growth. In Omeros Corporation's latest filings, the product still supports recurring niche sales rather than high-growth expansion.
OMIDRIA, established commercial franchise
OMIDRIA is Omeros Corporation’s only clearly commercialized business line, so it behaves like a classic cash cow in the BCG matrix. In 2025, the franchise’s value came from cash generation, not heavy growth spend, which is what you expect from a mature product. That maturity makes OMIDRIA the portfolio’s main source of near-term revenue support.
OMIDRIA, low-growth market
OMIDRIA sits in a low-growth cataract-surgery support market, where U.S. cataract procedures stay mature at about 4 million a year. That steady demand means Omeros Corporation does not need heavy promo spend, so OMIDRIA can protect margin and cash flow better than a fast-growth asset.
- Stable surgery volume supports demand
- Low growth cuts sales spend needs
- Maturity helps cash generation
OMIDRIA, legacy asset funding R and D
OMIDRIA is Omeros Corporation’s legacy cash cow: a mature, FDA-approved product whose commercial cash flow can help fund earlier-stage R and D. In a biotech portfolio, that matters because stable product revenue lowers reliance on outside capital and supports longer development cycles.
- OMIDRIA funds R and D spend
- Mature asset, not a growth driver
- Supports Omeros’s pipeline cash needs
OMIDRIA: Omeros’ Stable Cash Engine in Cataract Surgery
OMIDRIA is Omeros Corporation’s cash cow: a mature, FDA-approved product used in over 1 million procedures. It serves a steady U.S. cataract market of about 4 million surgeries a year, so demand is stable and sales spend stays lighter. In 2025, it remained the company’s main commercial cash source.
| Metric | Value |
|---|---|
| Procedures | 1M+ |
| U.S. cataract surgeries | ~4M/year |
| Status | Mature cash source |
Preview Before You Purchase
Omeros Corporation Reference Sources
The Omeros Corporation BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No demo content, no watermarks—just the complete, ready-to-use file. It’s fully formatted for clear strategic review and immediate use. Once purchased, the full version is delivered instantly.
Dogs
Narsoplimab, COVID-19 trial
Narsoplimab’s COVID-19 trial fits Dogs in Omeros Corporation’s BCG view: by end-2025, COVID-19 is no longer a high-growth market, so a pandemic-era study has limited commercial upside.
With Omeros Corporation still needing capital for higher-value programs, this asset looks like a weak strategic fit and a low-return use of R&D spend.
GPR174 inhibitors, preclinical
GPR174 inhibitors remain a discovery-stage asset for Omeros Corporation, with no clinical proof of concept yet. That means the program still has low share and highly uncertain commercial value, which fits a Dog in the BCG Matrix. In biotech, preclinical-only programs often face the highest attrition before first-in-human data.
CAR T-cell therapies, preclinical
Omeros Corporation’s CAR T-cell therapies remain preclinical, so they have not reached clinical commercialization or late-stage value inflection. Cell therapy is expensive and crowded: global CAR-T market revenue was about $5.5 billion in 2024 and is projected to exceed $20 billion by 2030, but most value still sits with approved, data-rich assets. Without human efficacy data, this Dogs bucket stays far from value creation.
Adoptive T-cell therapies, preclinical
Omeros Corporation's adoptive T-cell therapies are still preclinical, so they sit in the BCG "dog" bucket: low share, low visibility, and no near-term revenue. These programs face long timelines, high attrition, and usually need years of capital before any human data. In Omeros Corporation's 2025 filings, the company still reported no commercial sales from these assets.
- Preclinical only
- High failure risk
- No near-term cash flow
Broad GPCR discovery programs
Omeros Corporation’s broad GPCR discovery work spans multiple targets and disease areas, but it has not yet produced an approved product. That means the platform has scientific reach, yet little near-term revenue support, so it fits a dog profile in BCG terms.
For FY2025, the key point is still commercial: no marketed GPCR asset from this program, so cash flow depends on other Omeros Corporation assets and funding. Broad discovery breadth helps optionality, but without approval it stays a low-return, high-burn bucket.
- Many GPCR targets
- No approved product
- Weak near-term revenue
- Dog candidate in BCG
Omeros FY2025: All Dogs, No Sales, No Near-Term Cash Flow
Omeros Corporation’s Dogs are still low-share, low-return assets in FY2025: no approved product, no commercial sales, and no near-term cash flow. Narsoplimab’s COVID-19 study also has weak upside because the pandemic market is no longer growing.
GPR174 inhibitors, CAR T-cell therapies, adoptive T-cell therapies, and broad GPCR discovery remain preclinical or discovery-stage, so they carry high failure risk and long payback periods. In BCG terms, they consume capital now but do not yet create revenue.
| Asset | FY2025 status | BCG read |
|---|---|---|
| Narsoplimab COVID-19 | No clear growth | Dog |
| GPR174 inhibitors | Discovery-stage | Dog |
| CAR T / adoptive T | Preclinical | Dog |
| GPCR discovery | No approved product | Dog |
Question Marks
OMS405, Phase II opioid and nicotine dependence
OMS405 is a Phase II CNS and addiction program aimed at opioid and nicotine dependence, two large markets with high unmet need. Omeros has no market share yet here, so the asset is still pre-commercial and cash-consuming, like most Phase II shots on goal. That makes OMS405 a classic question mark: high upside, but no proven traction and no revenue.
OMS527, Phase I addiction, compulsive and movement disorders
OMS527 is still in Phase I, so its clinical value is unproven and it has no approved commercial position yet. The target areas, addiction, compulsive disorders, and movement disorders, address patient pools measured in millions, but Omeros Corporation still has to prove safety and efficacy before any revenue path opens.
OMS906, Phase I PNH
OMS906 in Phase I sits in a high-value PNH market, but it is still far behind leaders. PNH is ultra-rare, at about 10-20 cases per million, and approved drugs like Ultomiris and Empaveli already define care. That makes OMS906 a Question Mark: high growth potential, but no current market lead.
MASP-2 small molecules, preclinical
MASP-2 small molecules are still preclinical, so Omeros Corporation has no market share or product revenue here yet. The program spans four high-value targets: aHUS, IgAN, HSCT-TMA, and AMD, which gives it commercial upside if one asset reaches clinic and proves efficacy.
- Preclinical only
- 0% current market share
- 4 target diseases
- Commercial upside, no sales yet
Next-gen long-acting MASP-2 antibody, preclinical
This next-gen long-acting MASP-2 antibody is still a preclinical pipeline extension, not a marketed asset, so it adds no 2025 revenue today. A longer-acting dose profile could sharpen differentiation if Omeros Corporation gets it into the clinic, but the value is still tied to early-stage proof, not sales. For now, it fits the BCG "Question Mark" bucket: high upside, high execution risk.
Preclinical only; no product sales.
Longer-acting dosing may boost differentiation.
Value depends on clinic entry and data.
Omeros’ Pipeline: Big Markets, No Proof Yet
All four Omeros Corporation programs remain Question Marks: OMS405 and OMS527 target huge addiction markets, OMS906 is Phase I in PNH, and MASP-2 assets are still preclinical. With 0% share and no 2025 product revenue, their value depends on clinical proof, not sales.
| Asset | Stage | Signal |
|---|---|---|
| OMS405 | Phase II | Large TAM, no share |
| OMS527 | Phase I | Unproven |
| OMS906 | Phase I | PNH leader gap |
| MASP-2 | Preclinical | 4 indications |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.